Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase EARLY_PHASE1 1

Status

Active not recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3Genitourinary 1

Conditions

Breast Neoplasms 2Triple Negative Breast Neoplasms 1

Interventions

Fulvestrant 83Letrozole 77Paclitaxel 76pembrolizumab 72Specimen Handling 66Trastuzumab 62Carboplatin 57Magnetic Resonance Spectroscopy 51ribociclib 49Capecitabine 48Anastrozole 47pertuzumab 46palbociclib 43exemestane 40abemaciclib 40Cyclophosphamide 40Tamoxifen 39Biopsy 38Docetaxel 30trastuzumab deruxtecan 29Taxes 28Radiotherapy 28Gemcitabine 25Blood Specimen Collection 25130-nm albumin-bound paclitaxel 25olaparib 22Surveys and Questionnaires 22Standard of Care 22sacituzumab govitecan 20eribulin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Technetium Tc 99m Sestamibi × Breast × 90 days × Clear all
NCT02744053 2026-04-21

DCE-MRI and MBI in Assessing Tumor Response to Chemotherapy in Patients With Triple Negative Breast Cancer

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Active not recruiting
96 enrolled
Breast

Triple Negative Breast Neoplasms

NCT05042687 2026-04-15

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer

M.D. Anderson Cancer Center

Phase NA Recruiting
300 enrolled
Breast

Breast Neoplasms

NCT02324387 2026-03-09

Tc99m Sestamibi Molecular Breast Imaging

M.D. Anderson Cancer Center

Phase NA Active not recruiting
96 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡